Experience

The Chemistry Research Solution LLC - An Abzena Company

• United States
• Research Services
• 1 - 100 Employee

• Senior Scientist

  • 2012 - Present



Pfizer (formerly Wyeth)

• Research Scientist I

  • 2001 - 2010

  • Developed a synthetic route to novel scaffold for pain indication using a simple aldehyde oxidation as a key step. Completed parallel synthesis libraries exploring structure activity relationship (SAR) around new scaffold, resulting in potent compounds in the functional assay.• Expanded the SAR of the cardiovascular development compound by finding syntheses for fluorinated side chains. This gave a more potent compound with a similar pharmaceutical profile.• Was given responsibility for the preparation of a batch of the PR modulator for Ames testing. The sample was prepared and re-crystallized to obtain a pure sample. Additional analogs were made.• Overcame several synthetic obstacles in the preparation of 2 norepinephrine reuptake inhibitor (NRI) scaffolds by altering the route to the first scaffold and then for the 2nd scaffold incorporating microwave chemistry to drive a sluggish reaction. This gave new active NRI compounds.• Investigated the therapeutic potential of estrogen receptor beta (ER beta) targets. Two libraries prepared via Suzuki coupling yielded a novel potent and selective ER beta compound.• Delivered several parallel synthesis libraries for the cardiovascular project to enhance the SAR. Developed for one library a short synthesis of low molecular weight, polar, non-UV active amine starting materials that did not require any purification. Discovered for the other library a novel acylation reaction to prepare amides from an un-reactive sterically hindered cyclic amine. Subsequently, another team member used this reaction when no other chemistry worked for them.• Completed several parallel syntheses around various scaffolds for the osteoporosis project. One library of ureas was made by treating amine substrates with unsymmetrical N-cabonylimidazole ureas to give several active compounds, including one that compared favorably with the biological lead.

• Various Scientific positions of increasing importance

  • 1986 - 2001

  • Defined potential of D2 partial agonists (depression) leading to the discovery of novel active compounds.• Identified novel M1 agonists (Alzheimer’s disease). • Prepared anxiolytics (anxiety) and antidepressants targets. Batches of the lead compounds were synthesized when needed. Additional analogs of the lead compounds were created, one of which could not be made by the obvious route. An alternate synthesis was independently designed and executed.• Optimized H1-antagonist (antihistamine) activity. A competitor's H1-antagonist was prepared for testing against the lead for the purposes of patent protection.